JP7678756B2 - アゼパン誘導体 - Google Patents

アゼパン誘導体 Download PDF

Info

Publication number
JP7678756B2
JP7678756B2 JP2021551303A JP2021551303A JP7678756B2 JP 7678756 B2 JP7678756 B2 JP 7678756B2 JP 2021551303 A JP2021551303 A JP 2021551303A JP 2021551303 A JP2021551303 A JP 2021551303A JP 7678756 B2 JP7678756 B2 JP 7678756B2
Authority
JP
Japan
Prior art keywords
epiminoethano
naphtho
cyclopropylmethyl
hexahydro
azepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021551303A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021065898A1 (https=
Inventor
義一 渡邉
大祐 齊藤
康平 林田
広平 山元
真悠 並木
雄三 茂木
誠浩 谷田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Publication of JPWO2021065898A1 publication Critical patent/JPWO2021065898A1/ja
Application granted granted Critical
Publication of JP7678756B2 publication Critical patent/JP7678756B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021551303A 2019-09-30 2020-09-29 アゼパン誘導体 Active JP7678756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019179727 2019-09-30
JP2019179727 2019-09-30
PCT/JP2020/036868 WO2021065898A1 (ja) 2019-09-30 2020-09-29 アゼパン誘導体

Publications (2)

Publication Number Publication Date
JPWO2021065898A1 JPWO2021065898A1 (https=) 2021-04-08
JP7678756B2 true JP7678756B2 (ja) 2025-05-16

Family

ID=75338310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551303A Active JP7678756B2 (ja) 2019-09-30 2020-09-29 アゼパン誘導体

Country Status (8)

Country Link
US (1) US20230087342A1 (https=)
EP (1) EP4039331A4 (https=)
JP (1) JP7678756B2 (https=)
KR (1) KR20220071223A (https=)
CN (1) CN114761082A (https=)
AU (1) AU2020360928A1 (https=)
CA (1) CA3152485A1 (https=)
WO (1) WO2021065898A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022210479A1 (ja) * 2021-03-29 2022-10-06 日本ケミファ株式会社 アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143263A1 (ja) 2007-05-22 2008-11-27 Astellas Pharma Inc. １位置換テトラヒドロイソキノリン化合物
JP2010511717A (ja) 2006-12-05 2010-04-15 ニューロジェシックス， インコーポレイテッド プロドラッグおよびその作成ならびに使用方法
JP2015500245A (ja) 2011-12-05 2015-01-05 マリンクロッド エルエルシー ７員環ラクタムモルヒナンの製造のためのプロセス
WO2020085234A1 (ja) 2018-10-22 2020-04-30 日本ケミファ株式会社 モルヒナン誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US963460A (en) 1910-02-23 1910-07-05 Peter N Moore Roller side bearing.
JP2525552Y2 (ja) 1990-10-26 1997-02-12 株式会社間組 シャワールームユニット
GB9118597D0 (en) 1991-08-30 1991-10-16 Biocompatibles Ltd Polymer treatments
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
CA2296329A1 (en) 1997-07-24 1999-02-04 Masakazu Nakano Aminocycloalkane compounds
JP2008179554A (ja) 2007-01-24 2008-08-07 Toray Ind Inc ピロール縮合モルヒナン誘導体およびその医薬用途
WO2010021149A1 (ja) 2008-08-21 2010-02-25 武田薬品工業株式会社 酸分泌抑制スピロ化合物
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
MA40171A (fr) * 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2018125716A1 (en) * 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CA3055194A1 (en) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
JPWO2019045006A1 (ja) * 2017-08-31 2020-10-01 国立大学法人 筑波大学 モルヒナン誘導体
JP7348714B2 (ja) 2018-03-30 2023-09-21 古河電気工業株式会社 カーボンナノチューブ線材、カーボンナノチューブ被覆電線、カーボンナノチューブ線材の製造方法及びカーボンナノチューブ被覆電線の加工方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511717A (ja) 2006-12-05 2010-04-15 ニューロジェシックス， インコーポレイテッド プロドラッグおよびその作成ならびに使用方法
WO2008143263A1 (ja) 2007-05-22 2008-11-27 Astellas Pharma Inc. １位置換テトラヒドロイソキノリン化合物
JP2015500245A (ja) 2011-12-05 2015-01-05 マリンクロッド エルエルシー ７員環ラクタムモルヒナンの製造のためのプロセス
WO2020085234A1 (ja) 2018-10-22 2020-04-30 日本ケミファ株式会社 モルヒナン誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem.，2016年，24，2199-2205
Chem. Pharm. Bull.，1970年，18，1269-1273
ISHIKAWA, Kyoko et al，C-homomorphinan derivatives as lead compounds to obtain safer and more clinically useful analgesics，Chem. Pharm. Bull.，2017年，65，920-929
SUZUKI, Shinya et al.，Discovery of highly selective kappa-opioid receptor agnists: 10 alpha-hydroxy TRK-820 derivatives，Bioorganic & Medicinal Chemistry Letters，2017年，27，3920-3924

Also Published As

Publication number Publication date
CN114761082A (zh) 2022-07-15
WO2021065898A1 (ja) 2021-04-08
EP4039331A4 (en) 2024-01-17
KR20220071223A (ko) 2022-05-31
JPWO2021065898A1 (https=) 2021-04-08
US20230087342A1 (en) 2023-03-23
AU2020360928A1 (en) 2022-04-14
CA3152485A1 (en) 2021-04-08
EP4039331A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
AU2019249849B2 (en) BRM targeting compounds and associated methods of use
KR102482271B1 (ko) 낭포성 섬유증 막관통 전도성 조절인자의 조절제로서의 매크로사이클, 그의 약제학적 조성물, 낭포성 섬유증의 치료에서의 그의 용도, 및 그의 제조 방법
US12162872B2 (en) Cycloalkylurea derivative
JP2026509484A (ja) Ｋｒａｓモジュレーターおよびその使用
AU2019228568B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
WO2024259169A1 (en) Pyrimidine based modulators and uses thereof
BR112021001044A2 (pt) Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
KR20200101423A (ko) Nlrp3 인플라마좀 조절제로서의 설포닐 우레아 유도체
JP5780954B2 (ja) ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
JP2022517901A (ja) 環状尿素
US11352357B2 (en) Cycloalkylurea derivative
US20250074890A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
WO2023204308A1 (ja) オキサゼピン誘導体
TW202515851A (zh) Keap1抑制劑及其用途
WO2020085234A1 (ja) モルヒナン誘導体
JP7678756B2 (ja) アゼパン誘導体
WO2019045006A1 (ja) モルヒナン誘導体
WO2021132524A1 (ja) エポキシアゼパン誘導体
JP2024528614A (ja) ニトリルｓｕｍｏ阻害剤及びその使用
WO2022210479A1 (ja) アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用
WO2024204554A1 (ja) スピロ環状モルヒナン誘導体
RU2820289C2 (ru) Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1
HK40071875A (en) Azepan derivative
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
EP4568946A1 (en) Macrocyclic bcl6 degraders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250502

R150 Certificate of patent or registration of utility model

Ref document number: 7678756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150